{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:26:58Z","timestamp":1788532018637,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,4]]},"DOI":"10.7759\/cureus.115772","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:59:58Z","timestamp":1788530398000},"source":"Crossref","is-referenced-by-count":0,"title":["Bilateral Chronic Central Serous Chorioretinopathy Leads to Macular Atrophy: A Case Report"],"prefix":"10.7759","author":[{"given":"Othman","family":"Haddani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor R","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine","family":"Razzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Bouazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elbelhadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: update on pathophysiology and treatment","volume":"58","author":"Nicholson B","year":"2013","unstructured":"Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013, 58:103-126. 10.1016\/j.survophthal.2012.07.004","journal-title":"Surv Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001443","article-title":"Acute central serous chorioretinopathy: factors influencing episode duration","volume":"37","author":"Daruich A","year":"2017","unstructured":"Daruich A, Matet A, Marchionno L, De Azevedo JD, Ambresin A, Mantel I, Behar-Cohen F. Acute central serous chorioretinopathy: factors influencing episode duration. Retina. 2017, 37:1905-1915. 10.1097\/IAE.0000000000001443","journal-title":"Retina"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich A","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, et al.. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015, 48:82-118. 10.1016\/j.preteyeres.2015.05.003","journal-title":"Prog Retin Eye Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14201","article-title":"Central serous chorioretinopathy: a review","volume":"51","author":"Fung AT","year":"2023","unstructured":"Fung AT, Yang Y, Kam AW. Central serous chorioretinopathy: a review. Clin Exp Ophthalmol. 2023, 51:243-270. 10.1111\/ceo.14201","journal-title":"Clin Exp Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100865","article-title":"Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities","volume":"79","author":"Kaye R","year":"2020","unstructured":"Kaye R, Chandra S, Sheth J, Boon CJF, Sivaprasad S, Lotery A. Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities. Prog Retin Eye Res. 2020, 79:100865. 10.1016\/j.preteyeres.2020.100865","journal-title":"Prog Retin Eye Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100973","article-title":"Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders","volume":"86","author":"Spaide RF","year":"2022","unstructured":"Spaide RF, Gemmy Cheung CM, Matsumoto H, et al.. Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res. 2022, 86:100973. 10.1016\/j.preteyeres.2021.100973","journal-title":"Prog Retin Eye Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182953df4","article-title":"Pachychoroid pigment epitheliopathy","volume":"33","author":"Warrow DJ","year":"2013","unstructured":"Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013, 33:1659-1672. 10.1097\/IAE.0b013e3182953df4","journal-title":"Retina"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000331","article-title":"Pachychoroid neovasculopathy","volume":"35","author":"Pang CE","year":"2015","unstructured":"Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015, 35:1-9. 10.1097\/IAE.0000000000000331","journal-title":"Retina"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001907","article-title":"Peripapillary pachychoroid syndrome","volume":"38","author":"Phasukkijwatana N","year":"2018","unstructured":"Phasukkijwatana N, Freund KB, Dolz-Marco R, et al.. Peripapillary pachychoroid syndrome. Retina. 2018, 38:1652-1667. 10.1097\/IAE.0000000000001907","journal-title":"Retina"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.08.002","article-title":"The pachychoroid disease spectrum-and the need for a uniform classification system","volume":"3","author":"Siedlecki J","year":"2019","unstructured":"Siedlecki J, Schworm B, Priglinger SG. The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina. 2019, 3:1013-1015. 10.1016\/j.oret.2019.08.002","journal-title":"Ophthalmol Retina"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002","volume":"115","author":"Kitzmann AS","year":"2008","unstructured":"Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology. 2008, 115:169-173. 10.1016\/j.ophtha.2007.02.032","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2012.02848.x","article-title":"Central serous chorioretinopathy: a review of epidemiology and pathophysiology","volume":"41","author":"Liew G","year":"2013","unstructured":"Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013, 41:201-214. 10.1111\/j.1442-9071.2012.02848.x","journal-title":"Clin Exp Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S160956","article-title":"Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy","volume":"12","author":"Mohabati D","year":"2018","unstructured":"Mohabati D, van Rijssen TJ, van Dijk EH, et al.. Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. Clin Ophthalmol. 2018, 12:1061-1070. 10.2147\/OPTH.S160956","journal-title":"Clin Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13114","article-title":"Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of 'expanded spectra' - a review","volume":"46","author":"Dansingani KK","year":"2018","unstructured":"Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB. Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of 'expanded spectra' - a review. Clin Exp Ophthalmol. 2018, 46:189-200. 10.1111\/ceo.13114","journal-title":"Clin Exp Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000773","article-title":"Type 2 neovascularization secondary to age-related macular degeneration imaged by optical coherence tomography angiography","volume":"35","author":"El Ameen A","year":"2015","unstructured":"El Ameen A, Cohen SY, Semoun O, et al.. Type 2 neovascularization secondary to age-related macular degeneration imaged by optical coherence tomography angiography. Retina. 2015, 35:2212-2218. 10.1097\/IAE.0000000000000773","journal-title":"Retina"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.07.003","article-title":"Central serous chorioretinopathy: towards an evidence-based treatment guideline","volume":"73","author":"van Rijssen TJ","year":"2019","unstructured":"van Rijssen TJ, van Dijk EHC, Yzer S, et al.. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019, 73:100770. 10.1016\/j.preteyeres.2019.07.003","journal-title":"Prog Retin Eye Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftal.2020.07.023","article-title":"Update on the management of chronic central serous chorioretinopathy","volume":"96","author":"Moreno-Morillo FJ","year":"2021","unstructured":"Moreno-Morillo FJ, Fern\u00e1ndez-Vigo JI, G\u00fcemes-Villahoz N, Burgos-Blasco B, L\u00f3pez-Guajardo L, Donate-L\u00f3pez J. Update on the management of chronic central serous chorioretinopathy. Arch Soc Esp Oftalmol (Engl Ed). 2021, 96:251-264. 10.1016\/j.oftal.2020.07.023","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.06.020","article-title":"Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial","volume":"233","author":"van Rijssen TJ","year":"2022","unstructured":"van Rijssen TJ, van Dijk EH, Tsonaka R, et al.. Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol. 2022, 233:101-110. 10.1016\/j.ajo.2021.06.020","journal-title":"Am J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial","volume":"125","author":"van Dijk EH","year":"2018","unstructured":"van Dijk EH, Fauser S, Breukink MB, et al.. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology. 2018, 125:1547-1555. 10.1016\/j.ophtha.2018.04.021","journal-title":"Ophthalmology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001394","article-title":"Combined topical anti-inflammatory and oral acetazolamide in the treatment of central serous chorioretinopathy","volume":"96","author":"Wuarin R","year":"2019","unstructured":"Wuarin R, Kakkassery V, Consigli A, et al.. Combined topical anti-inflammatory and oral acetazolamide in the treatment of central serous chorioretinopathy. Optom Vis Sci. 2019, 96:500-506. 10.1097\/OPX.0000000000001394","journal-title":"Optom Vis Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32981-2","article-title":"Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial","volume":"395","author":"Lotery A","year":"2020","unstructured":"Lotery A, Sivaprasad S, O'Connell A, et al.. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020, 395:294-303. 10.1016\/S0140-6736(19)32981-2","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0460-4","article-title":"Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis","volume":"39","author":"Ji S","year":"2017","unstructured":"Ji S, Wei Y, Chen J, Tang S. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis. Int J Clin Pharm. 2017, 39:514-521. 10.1007\/s11096-017-0460-4","journal-title":"Int J Clin Pharm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/526221-bilateral-chronic-central-serous-chorioretinopathy-leads-to-macular-atrophy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:59:59Z","timestamp":1788530399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/526221-bilateral-chronic-central-serous-chorioretinopathy-leads-to-macular-atrophy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.115772","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}